Real-world data of triplet combination of pyrotinib, trastuzumab, and chemotherapy in HER2-positive metastatic breast cancer: a multicenter, retrospective study.
Shuhui YouDie SangFei XuTing LuoPeng YuanYizhao XieBi-Yun WangPublished in: Therapeutic advances in medical oncology (2023)
PyroHC shows promising efficacy and a satisfactory safety profile for treating HER2+ MBC, both as a first-line option and for heavily treated patients, including those with brain metastasis. Our findings suggest the duration and history of anti-HER2 therapy as potential predictors for PyroHC efficacy in advanced settings.
Keyphrases
- metastatic breast cancer
- newly diagnosed
- end stage renal disease
- ejection fraction
- white matter
- resting state
- epidermal growth factor receptor
- radiation therapy
- machine learning
- clinical trial
- stem cells
- big data
- functional connectivity
- bone marrow
- brain injury
- mesenchymal stem cells
- double blind
- artificial intelligence